XBI News and Press, SPDR Series Trust S&P Biotech From 03/26/24

2024-03-26 11:45:41 ET More on Consumer Discretionary Select Sector SPDR ETF, SPDR S&P Retail ETF, etc. Read the full article on Seeking Alpha For further details see: Cons Disc distribution & retail has the highest dispersion among S&P groups - MS

2024-03-22 11:15:00 ET Summary A positive January for U.S. stocks is typically a prelude to a positive year, with our analysis finding the correlation to hold 80% of the time since 1928. Stocks look well-positioned to outperform bonds and cash again this year, but high valuations ...

2024-03-21 15:21:09 ET Summary In the last week(s) we have put on tactical hedges/shorts across our portfolio. While the indices look a little vulnerable here, there are many high-quality companies and turnaround stories that are just beginning their turnaround. One thing I am...

2024-03-20 11:40:18 ET Summary BlackRock Health Sciences Term Trust has seen its discount narrow somewhat since our last update, but it remains attractive still. BMEZ utilizes a covered call writing strategy and also provides some private investments to help deliver performance. ...

2024-03-20 04:50:32 ET Summary Shares of biotechnology companies have been lagging behind the S&P 500 Index. This underperformance of XBI relative to the S&P 500, however, has only made the opportunity even more attractive to us. Evidence of improving fundamentals and ...

2024-03-19 10:16:19 ET Summary Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows. Deal volume should remain strong in 2024 as large pharma concerns have large cash balances, face key patent expirations ...

2024-03-19 02:50:00 ET Summary Typically, a back-up in rates has led to a sell-off in stocks. We believe the current environment is different for three reasons: the degree of the move in rates, current economic cycle, and strength of mega-cap technology. In this environment, we wo...

2024-03-15 09:26:51 ET More on Genmab Genmab: Recent Updates Support The Growth Narrative Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) AbbVie/ Genmab win FDA priority review for lymp...

2024-03-14 14:54:38 ET More on Impel NeuroPharma, Infinity Pharmaceuticals, etc. Sorrento wins DoJ’s venue-based challenge to bankruptcy filing Scilex and Sorrento settle with Virpax and its founder Anthony Mack Financial information for Impel NeuroPharma ...

2024-03-13 13:29:04 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...